Cargando…

Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy

BACKGROUND: Pharmacokinetics and pharmacodynamics of drugs in elderly individuals differ from those in younger adults; thus, adverse drug events (ADEs) are common in older patients with polypharmacy because co-existing comorbidities elevate the risk of ADEs occurring. However, ADEs have not yet been...

Descripción completa

Detalles Bibliográficos
Autores principales: Negishi, Akio, Oshima, Shinji, Horii, Norimitsu, Mutoh, Mizue, Inoue, Naoko, Numajiri, Sachihiko, Ohshima, Shigeru, Kobayashi, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984209/
https://www.ncbi.nlm.nih.gov/pubmed/33367976
http://dx.doi.org/10.1007/s40801-020-00221-8
_version_ 1783668023953981440
author Negishi, Akio
Oshima, Shinji
Horii, Norimitsu
Mutoh, Mizue
Inoue, Naoko
Numajiri, Sachihiko
Ohshima, Shigeru
Kobayashi, Daisuke
author_facet Negishi, Akio
Oshima, Shinji
Horii, Norimitsu
Mutoh, Mizue
Inoue, Naoko
Numajiri, Sachihiko
Ohshima, Shigeru
Kobayashi, Daisuke
author_sort Negishi, Akio
collection PubMed
description BACKGROUND: Pharmacokinetics and pharmacodynamics of drugs in elderly individuals differ from those in younger adults; thus, adverse drug events (ADEs) are common in older patients with polypharmacy because co-existing comorbidities elevate the risk of ADEs occurring. However, ADEs have not yet been characterised based on the elderly patients of Japanese origin and polypharmacy. OBJECTIVE: The 100 most commonly reported ADEs were grouped into four classes (Class 1–Class 4) based on elderly patients with polypharmacy. PATIENTS AND METHODS: In this study, logistic regression analysis was performed using cases recorded in the Japanese Adverse Drug Event Report (JADER) database. RESULTS: ADEs in elderly patients treated with polypharmacy—in whom the risk of electrolyte abnormalities, renal and respiratory disorders, and coagulopathy was high—were categorised as ‘Class 1 [E(+), P(+)]’, while ADEs in elderly patients not treated with polypharmacy—in whom the risk of delirium and fall was high—were categorised as ‘Class 2 [E(+), P(−)]’. When there was no association with being elderly, ADEs associated with polypharmacy that carried a high risk of myelosuppression and infection were categorised as ‘Class 3 [E(−), P(+)]’, and allergic ADEs that were not affected by being elderly or polypharmacy, were categorised as ‘Class 4 [E(−), P(−)]’. Class 1 events as well as Class 3 ADEs occurred more frequently in females than in males, whereas Class 3 ADEs (deep vein thrombosis and pulmonary embolism) occurred more frequently in males. CONCLUSIONS: Class 1 and Class 2 ADEs should be investigated in analyses that focus on individual drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-020-00221-8.
format Online
Article
Text
id pubmed-7984209
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79842092021-04-12 Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy Negishi, Akio Oshima, Shinji Horii, Norimitsu Mutoh, Mizue Inoue, Naoko Numajiri, Sachihiko Ohshima, Shigeru Kobayashi, Daisuke Drugs Real World Outcomes Original Research Article BACKGROUND: Pharmacokinetics and pharmacodynamics of drugs in elderly individuals differ from those in younger adults; thus, adverse drug events (ADEs) are common in older patients with polypharmacy because co-existing comorbidities elevate the risk of ADEs occurring. However, ADEs have not yet been characterised based on the elderly patients of Japanese origin and polypharmacy. OBJECTIVE: The 100 most commonly reported ADEs were grouped into four classes (Class 1–Class 4) based on elderly patients with polypharmacy. PATIENTS AND METHODS: In this study, logistic regression analysis was performed using cases recorded in the Japanese Adverse Drug Event Report (JADER) database. RESULTS: ADEs in elderly patients treated with polypharmacy—in whom the risk of electrolyte abnormalities, renal and respiratory disorders, and coagulopathy was high—were categorised as ‘Class 1 [E(+), P(+)]’, while ADEs in elderly patients not treated with polypharmacy—in whom the risk of delirium and fall was high—were categorised as ‘Class 2 [E(+), P(−)]’. When there was no association with being elderly, ADEs associated with polypharmacy that carried a high risk of myelosuppression and infection were categorised as ‘Class 3 [E(−), P(+)]’, and allergic ADEs that were not affected by being elderly or polypharmacy, were categorised as ‘Class 4 [E(−), P(−)]’. Class 1 events as well as Class 3 ADEs occurred more frequently in females than in males, whereas Class 3 ADEs (deep vein thrombosis and pulmonary embolism) occurred more frequently in males. CONCLUSIONS: Class 1 and Class 2 ADEs should be investigated in analyses that focus on individual drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-020-00221-8. Springer International Publishing 2020-12-23 /pmc/articles/PMC7984209/ /pubmed/33367976 http://dx.doi.org/10.1007/s40801-020-00221-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research Article
Negishi, Akio
Oshima, Shinji
Horii, Norimitsu
Mutoh, Mizue
Inoue, Naoko
Numajiri, Sachihiko
Ohshima, Shigeru
Kobayashi, Daisuke
Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title_full Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title_fullStr Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title_full_unstemmed Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title_short Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
title_sort categorisation of pharmaceutical adverse events using the japanese adverse drug event report database: characteristic adverse drug events of the elderly treated with polypharmacy
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984209/
https://www.ncbi.nlm.nih.gov/pubmed/33367976
http://dx.doi.org/10.1007/s40801-020-00221-8
work_keys_str_mv AT negishiakio categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT oshimashinji categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT horiinorimitsu categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT mutohmizue categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT inouenaoko categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT numajirisachihiko categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT ohshimashigeru categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy
AT kobayashidaisuke categorisationofpharmaceuticaladverseeventsusingthejapaneseadversedrugeventreportdatabasecharacteristicadversedrugeventsoftheelderlytreatedwithpolypharmacy